【摘 要】
：
Objective To assess the efficacy and safety of neoadjuvant chemotherapy (NAC) for advanced gastric cancer (AGC).Methods By searching electronic databases (PubMed, Embase, Cochrane Library) and ASCO pr
【机 构】
：
Department of General Surgery, the First Affiliated Hospital of Chongqing Medical University
【出 处】
：
2013年肿瘤多学科综合诊治新进展学术研讨会
论文部分内容阅读
Objective To assess the efficacy and safety of neoadjuvant chemotherapy (NAC) for advanced gastric cancer (AGC).Methods By searching electronic databases (PubMed, Embase, Cochrane Library) and ASCO proceedings from1990 to 2012, all randomized controlled trials (RCTs) which compared the effect of NAC combined surgery versus surgery alone in gastric cancer would be included.All calculations and statistical tests were performed using RevMan 5.0 software.Results 12 RCTs with a total of 1820 patients were included.All patients had locally advanced but resectable gastric cancer and received NAC.NAC can slightly improve the survival rate [OR =1.32, 95% confidence interval (CI): 1.07-1.64, P=0.01], little or no significant benefits were suggested in subgroup analyses between different population and regimens either.It can significantly improved the 3-year progression-free survival (PFS) [OR: 1.85,(1.39, 2.46), P <0.0001], tumor down-staging rate [OR :1.71,(1.26, 2.33), P =0.0006]and R0 resection rate[OR: 1.38,(1.08, 1.78) P=0.01] of patients with advanced gastric cancer.There were no difference between the two arms,in terms of relapse rates [OR: 1.03, (0.60, 1.78), P=0.92], operative complications[OR: 1.20,(0.90, 1.58), P=0.21], perioperative mortality [OR: 1.14, (0.64, 2.05), P=0.65] and grade 3/4 adverse effects.Conclusion NAC is effective and safe.It needs further prospective multinational multicenter RCTs to define the clinical benefits of NAC and the most effective strategies for AGC.
其他文献
Objective Side population (SP) cells may play a crucial role in tumorigenesis and the recurrence of cancer.Many kinds of cell lines and tissues have demonstrated the presence of SP cells, including co
目的 研究胸腺素alpha原对调节性T淋巴细胞的调节作用。方法 以小鼠肝癌细胞H22为材料制备小鼠原位肝癌动物模型，同时应用重组人alpha原进行干预，观察对肝癌生长的抑制作用，同时应用流式细胞仪技术对小鼠调节性T淋巴细胞进行检查，考察alpha原对其水平影响。结果 实验证明，胸腺素alpha原能够有效抑制原位肝癌的生长，同时发现胸腺素alpha原能够明显抑制调节性T淋巴细胞的水平。结论 实验结果
Objective Combined small cell lung cancer (CSCLC) is currently considered a subset of SCLC and have been reported to account for less than 1-3.2% of all SCLCs.Accurate understanding of CSCLCs is of gr
目的 探讨c-Myc在骨髓基质细胞介导的急性髓细胞白血病(AML)细胞耐药中的作用,从肿瘤微环境的角度探索AML耐药的分子机制.方法 将AML细胞系U937,KG1a及明确诊断AML患者的原代细胞与健康供者的骨髓基质细胞(MSC)共培养,以细胞单独培养作为对照.流式细胞术(FCM)及膜联蛋V(AnnexinV)/碘化丙啶(PI)双染色法比较两种培养条件下AML细胞对米托蒽醌诱导凋亡的差异；West
目的 探讨局部粘着斑激酶(FAK)在人高转移肝癌细胞株MHCC97-H的表达情况,不同浓度的舒尼替尼在不同时间点对肝癌细胞株的凋亡诱导情况,以及对FAK蛋白表达水平的影响.方法 采用免疫荧光检测舒尼替尼作用前后MHCC97-H肝癌细胞株中FAK的表达情况,采用流式细胞仪检测0、2.5、5、10umol/L浓度的索拉非尼在24、48和72h时间点对肝癌细胞的凋亡抑制情况,并用western-blot
目的 将白色芸豆防御素基因(defensin-byd)导入肺腺癌细胞株A549中表达,验证其是否有抗肿瘤作用及其机制.方法 基因工程技术构建真核表达质粒PCDNA3.1-defensin-byd,脂质体将其导入A549细胞中表达,磺酰罗丹明B(Sulforhodamine B,SRB).检测其抗肿瘤活性,流式细胞术、western blot初步探讨其抗肿瘤机制.结果 defensin-byd可显著
目的 研究研究斑蝥酸钠维生素B6(sodium cantharidinate,SCA)体外诱导胶质母细胞瘤U87凋亡作用及其机制.方法 利用MTT法检测0.625,1.25,2.5,5ug/mL SCA在24h,48h,72h对U87的生长抑制作用,倒置显微镜观察U87的形态学变化,利用流式细胞术分别检测SCA作用12h,24h后U87细胞凋亡率及细胞周期阻滞.RT-PCR分析SCA作用24小时后
Evidence shows that Bcl-2 family members play a direct role in the development of some human malignancies.However, the mechanism by which Bcl-2 may influence tumor cell invasion and metastasis remains
目的 肿瘤组织通常存在于缺氧环境中,糖酵解作用增强.为了避免凋亡,及时泵出细胞内H+,肿瘤细胞常高表达质子泵转运蛋白(v-ATPase)及Na+-H+交换泵(NHE).因此,我们联合使用埃索美拉唑与阿米洛利,观察对荷瘤裸鼠肿瘤生长转移的影响,并探讨其内在机制.方法 将人肺癌A549细胞接种于裸鼠背部皮下建立移植瘤模型,当肿瘤长150mm3时,随机分为2组：对照组与联合用药组(埃索美拉唑40mg/k
目的 揭示细胞衰老与慢性肝损伤至肝细胞肝癌的发病机制。方法 通过临床观测及Pubmed相关文献复习。结果 发现颇为丰富的研究资料显示，众多与肝癌发生相关的危险因素的基本致癌机制是慢性持续性肝损伤。即慢性肝损伤是肝细胞癌的基本成因。频繁的抗损伤修复导致肝细胞早衰性衰老使肝干细胞突变几率增大。结论 慢性肝脏损害可致肝细胞衰老并刺激肝卵原细胞(肝祖细胞)活跃增殖，后者属于分化前途未定的多分化潜能细胞，具